Results 91 to 100 of about 921,366 (160)
Background CD1d is a monomorphic antigen presentation molecule expressed in several hematologic malignancies. Alpha-galactosylceramide (α-GalCer) is a glycolipid that can be presented to cytotoxic CD1d-restricted T cells.
Davide Bagnara +12 more
doaj +1 more source
α-Galactosylceramide (α-GalCer) is a prototypical antigen recognized by natural killer T (NKT) cells, a subset of T cells crucial for immune regulation.
Jesang Lee +3 more
doaj +1 more source
Conformationally Restricted Analogues of α-Galactosylceramide as Adjuvant in COVID-19 Subunit Vaccine. [PDF]
Hu X +6 more
europepmc +1 more source
Κριτική - Έτος Α' τευχ. 1-12 (15 Ιουνίου 1923 - 30 Μαΐου 1924)
Στο Έτος Α’ περιλαμβάνονται 12 ...
core
Ability of IDO To Attenuate Liver Injury in α-Galactosylceramide–Induced Hepatitis Model
IDO converts tryptophan to l-kynurenine, and it is noted as a relevant molecule in promoting tolerance and suppressing adaptive immunity. In this study, we examined the effect of IDO in α-galactosylceramide (α-GalCer)–induced hepatitis.
Hiroyasu Ito +10 more
core +1 more source
Characterization of a Glycolipid Synthase Producing α-Galactosylceramide in Bacteroides fragilis. [PDF]
Caballé M, Faijes M, Planas A.
europepmc +1 more source
Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, α-galactosylceramide
A number of studies have shown that the natural killer T cell (NKT) ligand α-galactosylceramide (α-GalCer) serves as an adjuvant for various vaccines, including viral vaccines, parasite vaccines and protein vaccines.
Zhang, W +21 more
core +1 more source
Summary Myocarditis is an inflammation of the myocardium which often follows virus infections. Coxsackievirus B3 (CVB3), as a marker of the enterovirus group, is one of the most important infectious agents of virus-induced myocarditis ...
Y Wang +8 more
core +1 more source
Background Metastatic breast cancer is a leading cause of cancer death in woman. Current treatment options are often associated with adverse side effects and poor outcomes, demonstrating the need for effective new treatments.
Adam Nelson +6 more
doaj +1 more source
Background: Intranasal (I.N.) vaccination holds promise to elicit mucosal immunity that counters respiratory pathogens at the site of infection. For subunit protein vaccines, immunostimulatory adjuvants are typically required.
Yang Jiao +10 more
doaj +1 more source

